News & Events about Geron Corporation.
Business Wire
2 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an Expanded Access Protocol (EAP) is available for imetelstat, the Companys first-in-class telomerase inhibitor. As allowed under the U.S. Food and Drug Administration (FDA) policies, companies...
Geron (NASDAQ:GERN Get Rating) and Theseus Pharmaceuticals (NASDAQ:THRX Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, ...
Business Wire
3 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to...
Business Wire
3 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Companys first-in-class telomerase inhibitor, in patients with acute myeloid...
Business Wire
3 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence (TI), evidence for disease-modifying activity and favorable fatigue patient-reported outcomes (PRO) in...